New & Notable
GLP-1 therapies set to top global drug sales in 2026
GLP-1 drugs are on track to dominate this year's global biopharmaceutical sales rankings, a recent report says, marking a shift in where the industry's biggest money-makers now sit.
Pfizer dips on new data for obesity drug acquired in $10B deal
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
— BioPharma Dive
Novo combination obesity shot meets goal in diabetes trial
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly’s Zepbound.
— BioPharma Dive
ConcertAI unveils agentic AI tool to cut trial timelines, costs
ConcertAI has rolled out Accelerated Clinical Trials, an agentic AI platform that can cut trial timelines by 10–20 months and study design time by up to 50%, the company says.
AstraZeneca leans into obesity, striking deal with China’s CSPC
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Novo expands diabetes partnership with Aspect Biosystems
Novo Nordisk and Canadian bioprinting company Aspect Biosystems build on their 2023 deal to develop cell-based treatments for diabetes.
-
Trust concerns hinder agentic AI adoption, orchestration
Despite significant investment, most pharmaceutical and life sciences companies are struggling to bring agentic AI into production, a new report says.
-
Nvidia partners with Lilly to launch $1B AI drug discovery lab
Nvidia and Eli Lilly team up to invest $1 billion in a new AI lab to speed up drug discovery using Nvidia's BioNeMo platform and its next-gen Vera Rubin architecture.
-
Novo's Wegovy pill hits the market with a $149 cash-pay price
Novo Nordisk has launched oral Wegovy in the U.S., with cash-pay pricing starting at $149 per month for the lowest doses and ranging up to $299 for higher doses.
-
The FDA approves the first GLP-1 weight loss pill
The FDA has approved the oral version of Novo Nordisk's popular injectable obesity drug Wegovy, making it the first GLP-1 pill cleared for weight loss.
-
Novo submits its next-gen obesity drug for FDA approval
Novo Nordisk has filed for FDA approval of its next-generation, combination obesity drug, CagriSema, with a review expected next year.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.